Clinical Trial Search

Primary: The Primary Endpoint of the Study is the Percent of Eosinophils in the Bronchoalveolar Lavage Fluid After Segmental Allergen Challenge, Before and After Mepolizumab…

Primary: Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1. — 74; 35; 56; 12 Participants…

Primary: Change in Eosinophil Numbers Per High Power Field Proximally and Distally Between Baseline and Post-treatment and Between Both Groups — 0.6; -7.5 perecentage of eos per…

Primary: Fold Increase in ASM Proliferation Following Incubation With Eosinophils. — 2; 2 Fold increase in ASM cell proliferation — p=<0.05

Primary: Number of Participants With Complete Response to Dysphagia — 9; 6 participants — p=0.74

Primary: Number of Participants With Change in Sputum Markers by End of Study — 0; 0 Participants

Primary: Change From Baseline in Total Subepithelial Eosinophils at the End of Week 78 (End of Treatment) — -5.807; -5.890; 1.555; -5.626 cells/mm^2

Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53

Primary: Number of Participants Who Responded — 7; 4 participants

Primary: Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of…

Primary: Airway Resistance at 5 Hz (R5) at Baseline (Pre-mepolizumab Initiation) — 0.51; 0.39; 0.43 kPa/L/s

Primary: Number of Clinical Asthma Exacerbations (CAEs) During 52 Weeks of Treatment — 0.52; 0.41 events — p=0.194

Primary: Number and Percentage of Patients With a Positive Autoantibody ELISA — 19; 4; 3; 4 Participants

Primary: Change From Baseline in the Expression of FcεRI Receptors of Blood Basophils — -84.4; 27.7 Percent change in MFI

Primary: Histological Response to Treatment — 11; 16; 7; 12 Participants — p=1.00

Primary: Mean Change in Dysphagia Score — 15.4; 8.3 score on a scale — p=0.14

Primary: Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment — 1.804; 0.904 CAEs in 52 weeks — p=<0.0001

Primary: Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) — 10; 19; 14; 16 Participants — p=0.001

Primary: Mean Change From Baseline (BL) in St. George's Respiratory Questionnaire (SGRQ) Score at Week 24 — -7.9; -15.6 Scores on a scale — p=<0.001

Primary: Rate of Clinically Significant Exacerbations of Asthma — 0.45; 1.31 Exacerbations per year — p=<0.001

Primary: Change in Blood Absolute Eosinophil Count From Baseline to Week 12 — 0.8980; 0.4031; 0.3056; 0.2051 ratio to baseline — p=<.0001

Primary: Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment — 2.115; 0.859 CAEs in 52 weeks — p=<0.0001

Primary: Asthma Exacerbations During 52 Weeks Preceding Treatment Initiation (as Assessed at Baseline) and at the 24th and 52nd Week of the Treatment — 3; 0; 0 number of asthma…

Primary: Peak Esophageal Eosinophil Count — 57.3; 71.3 Peak # of eosinophils counted per field

Primary: Number of Participants With Histologic Response at the Final Treatment Period Evaluation (Week 16) — 1; 113; 104; 100 Participants — p=<0.001

Primary: Percentage Decrease of Sputum Eosinophils From Baseline to End of Therapy (6 Months) — 11.28; 7.07 percentage

Primary: Change From Baseline in 24-hour Cough Frequency at 14 Weeks — 17.0; 17.0; 12.6; 10.6 Coughs/hour — p=0.99

Primary: Differentially Expressed Genes — 149 differentially expressed gene

Primary: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks — 0.56; 1.08 Exacerbation per participant per year — p=<0.001

Primary: Esophageal Eosinophilia (Number of Eosinophils in the Esophagus) — 5.3 eosinophils/high power field